# Adaptive Biotechnologies Corp

Summary updated: 2026-10-02T13:19:03.627462Z
Canonical: https://finbar.com/research/companies/adaptive-biotechnologies-corp

## Overview

Adaptive Biotechnologies is a biotechnology company focused on immune medicine. It uses proprietary technologies to decode the adaptive immune system and develop clinical products and services, with the stated mission of translating the immune system’s genetic language into tools to diagnose and treat disease. [1](https://app.finbar.com/go?id=P121342574)[2](https://www.adaptivebiotech.com/our-story/)

Its offerings include clonoSEQ, a clinical diagnostic test for detecting and monitoring measurable residual disease in certain blood cancers, and immune-receptor sequencing, data and discovery services for biopharmaceutical partners. [3](https://app.finbar.com/go?id=P56301912)[4](https://app.finbar.com/go?id=P146022841) The company is headquartered in Seattle, Washington; the available sources do not establish a broader geographic footprint. [5](https://app.finbar.com/go?id=P62073110)

Adaptive reported $277.0 million in revenue for 2025 and $142.4 million for the six months ended June 30, 2026. [6](https://app.finbar.com/go?id=T10942757)[7](https://app.finbar.com/go?id=T16712978) A third-party source reported 624 employees as of December 31, 2025. [8](https://stockanalysis.com/stocks/adpt/employees/)
[1](https://app.finbar.com/go?id=P121342574)[2](https://www.adaptivebiotech.com/our-story/)[3](https://app.finbar.com/go?id=P56301912)[4](https://app.finbar.com/go?id=P146022841)[5](https://app.finbar.com/go?id=P62073110)[6](https://app.finbar.com/go?id=T10942757)[7](https://app.finbar.com/go?id=T16712978)[8](https://stockanalysis.com/stocks/adpt/employees/)[2](https://www.adaptivebiotech.com/our-story/)[8](https://stockanalysis.com/stocks/adpt/employees/)

## Products & services

clonoSEQ is Adaptive Biotechnologies’ next-generation sequencing diagnostic test for detecting and monitoring measurable residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The test can detect cancer at a sensitivity of as few as one cancer cell in one million; for other lymphoid cancers, including diffuse large B-cell lymphoma and mantle cell lymphoma, it is available as a CLIA-validated laboratory-developed test. [9](https://app.finbar.com/go?id=P146022840)[10](https://www.adaptivebiotech.com/clonoseq-mrd-test/)

MRD services include clinical testing and reports for physicians, sample testing for biopharmaceutical drug development and clinical trials, and technology transfers that enable international partner laboratories to deliver results. [11](https://app.finbar.com/go?id=P146022691) The company’s Immune Medicine platform sequences and characterizes T-cell and B-cell receptors and supports data licensing and target discovery. It has also used TCR–antigen prediction models and AI/ML to connect T-cell receptors with disease antigens. In July 2026, Adaptive said it would wind down its research-use-only Adaptive Immunosequencing TCR-sequencing offering and focus Immune Medicine on datasets, AI/ML models, and autoimmune target discovery. [12](https://app.finbar.com/go?id=P95925985)[4](https://app.finbar.com/go?id=P146022841)[13](https://app.finbar.com/go?id=P146022846)

For the first half of 2026, MRD generated $133.3 million of $142.4 million in revenue (about 93.6%); Immune Medicine generated $9.2 million (about 6.4%). [7](https://app.finbar.com/go?id=T16712978) For full-year 2025, MRD contributed $212.3 million of $277.0 million (about 76.7%). These are business-area figures, not revenue broken out by individual product; 2025 Immune Medicine revenue included a Genentech collaboration that was no longer a revenue source after September 2025. [6](https://app.finbar.com/go?id=T10942757)[11](https://app.finbar.com/go?id=P146022691)
[9](https://app.finbar.com/go?id=P146022840)[10](https://www.adaptivebiotech.com/clonoseq-mrd-test/)[11](https://app.finbar.com/go?id=P146022691)[12](https://app.finbar.com/go?id=P95925985)[4](https://app.finbar.com/go?id=P146022841)[13](https://app.finbar.com/go?id=P146022846)[7](https://app.finbar.com/go?id=T16712978)[7](https://app.finbar.com/go?id=T16712978)[7](https://app.finbar.com/go?id=T16712978)[7](https://app.finbar.com/go?id=T16712978)[6](https://app.finbar.com/go?id=T10942757)[6](https://app.finbar.com/go?id=T10942757)[6](https://app.finbar.com/go?id=T10942757)[10](https://www.adaptivebiotech.com/clonoseq-mrd-test/)

## Geographic presence

Adaptive Biotechnologies’ identified operating footprint is in the United States. Its headquarters and laboratory are in Seattle, Washington; the company also lists a Bothell, Washington site for manufacturing, quality control, engineering and warehousing, and a cellular-immunology research and development lab in South San Francisco, California. [14](https://app.finbar.com/go?id=P146022676)[15](https://app.finbar.com/go?id=P83242587)[16](https://www.adaptivebiotech.com/contact-us/)

The 2025 Form 10-K describes a South San Francisco office and laboratory lease of approximately 7,700 square feet, which commenced in February 2026. The filing reports revenue by business segment, but the reviewed materials do not provide revenue by country or region or employee distribution by geography. No non-U.S. operating location was identified in the reviewed sources. [17](https://app.finbar.com/go?id=P61761038)[6](https://app.finbar.com/go?id=T10942757)
[14](https://app.finbar.com/go?id=P146022676)[15](https://app.finbar.com/go?id=P83242587)[16](https://www.adaptivebiotech.com/contact-us/)[17](https://app.finbar.com/go?id=P61761038)[6](https://app.finbar.com/go?id=T10942757)[16](https://www.adaptivebiotech.com/contact-us/)

## Business segments

Adaptive Biotechnologies reports two operating and reportable segments: Minimal Residual Disease (MRD) and Immune Medicine [18](https://app.finbar.com/go?id=P76281171). MRD focuses on next-generation sequencing tests that measure residual cancer in patients, including clonoSEQ clinical testing and testing for biopharma and academic drug development [19](https://app.finbar.com/go?id=P49933851). Immune Medicine applies immune-receptor data and computational biology to research and product development, with activities including sample testing, data licensing and target discovery [20](https://app.finbar.com/go?id=P17939008)[21](https://app.finbar.com/go?id=P13470282).

By FY2025 revenue, MRD contributed approximately 77% ($212.334 million) and Immune Medicine approximately 23% ($64.642 million) [22](https://app.finbar.com/go?id=T11107594). The mix differed in Q1 2026: MRD contributed approximately 95% ($67.093 million) and Immune Medicine approximately 5% ($3.781 million) of reported segment revenue [23](https://app.finbar.com/go?id=T3305500).
[18](https://app.finbar.com/go?id=P76281171)[19](https://app.finbar.com/go?id=P49933851)[20](https://app.finbar.com/go?id=P17939008)[21](https://app.finbar.com/go?id=P13470282)[22](https://app.finbar.com/go?id=T11107594)[22](https://app.finbar.com/go?id=T11107594)[23](https://app.finbar.com/go?id=T3305500)[23](https://app.finbar.com/go?id=T3305500)

## Company history

Adaptive Biotechnologies was incorporated in Washington as Adaptive TCR Corporation on September 8, 2009, by brothers Chad Robins and Harlan Robins; its early work included developing large-scale T-cell immunosequencing technology. [24](https://app.finbar.com/go?id=P63943741) [25](https://app.finbar.com/go?id=P179080955) The company launched its immunoSEQ research product in 2010 and adopted the name Adaptive Biotechnologies Corporation in 2011. [26](https://www.adaptivebiotech.com/timeline/) [24](https://app.finbar.com/go?id=P63943741) In 2015, it acquired Sequenta, adding technology and capabilities related to sequencing-based measurement of minimal residual disease (MRD). [24](https://app.finbar.com/go?id=P63943741)

Adaptive established a strategic research collaboration with Microsoft in 2017 to apply machine learning to mapping T-cell receptors to antigens. [27](https://app.finbar.com/go?id=P179080617) [28](https://app.finbar.com/go?id=P179080662) In 2018, the FDA granted clonoSEQ authorization to monitor MRD in multiple myeloma and B-cell acute lymphoblastic leukemia, and Adaptive entered an oncology collaboration with Genentech. [29](https://app.finbar.com/go?id=P179080494) [30](https://app.finbar.com/go?id=P179080845) Adaptive went public on Nasdaq in 2019, with its IPO closing on July 1. [31](https://app.finbar.com/go?id=P179081363) [32](https://app.finbar.com/go?id=P179081613) In 2022, it partnered with Epic to integrate clonoSEQ into the electronic medical record system. [33](https://app.finbar.com/go?id=P119049474)
[24](https://app.finbar.com/go?id=P63943741)[25](https://app.finbar.com/go?id=P179080955)[27](https://app.finbar.com/go?id=P179080617)[28](https://app.finbar.com/go?id=P179080662)[29](https://app.finbar.com/go?id=P179080494)[30](https://app.finbar.com/go?id=P179080845)[31](https://app.finbar.com/go?id=P179081363)[32](https://app.finbar.com/go?id=P179081613)[33](https://app.finbar.com/go?id=P119049474)[26](https://www.adaptivebiotech.com/timeline/)

## Sources

1. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P121342574)
2. [www.adaptivebiotech.com](https://www.adaptivebiotech.com/our-story/)
3. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P56301912)
4. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P146022841)
5. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P62073110)
6. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=T10942757)
7. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=T16712978)
8. [stockanalysis.com](https://stockanalysis.com/stocks/adpt/employees/)
9. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P146022840)
10. [www.adaptivebiotech.com](https://www.adaptivebiotech.com/clonoseq-mrd-test/)
11. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P146022691)
12. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P95925985)
13. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P146022846)
14. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P146022676)
15. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P83242587)
16. [www.adaptivebiotech.com](https://www.adaptivebiotech.com/contact-us/)
17. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P61761038)
18. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P76281171)
19. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P49933851)
20. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P17939008)
21. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 1)](https://app.finbar.com/go?id=P13470282)
22. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=T11107594)
23. [Adaptive Biotechnologies Corp — Full financial report (2026 Q 1)](https://app.finbar.com/go?id=T3305500)
24. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P63943741)
25. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179080955)
26. [www.adaptivebiotech.com](https://www.adaptivebiotech.com/timeline/)
27. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179080617)
28. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179080662)
29. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179080494)
30. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179080845)
31. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179081363)
32. [Adaptive Biotechnologies Corp — Full financial report (2019 Y)](https://app.finbar.com/go?id=P179081613)
33. [Adaptive Biotechnologies Corp — Full financial report (2025 Y)](https://app.finbar.com/go?id=P119049474)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.